$PFE with the breakout Very similar to AMD and MSFT charts, PFE is starting to breakout after 20+ years. I'm starting a position with intent to add going forward. 6-12 months i'm targeting $80-85 area.
PFIZ34 trade ideas
$PFE with a Bullish outlook following its earnings #Stocks The PEAD projected a Bullish outlook for $PFE after a Positive over reaction following its earnings release placing the stock in drift B with an expected accuracy of 66.67%.
If you would like to see the Drift for another stock please message us. Also click on the Like Button if this was useful and follow us or join us.
Pfizer | Fundamental Analysis | LONG SETUP | MUST READ 🔔Some people say that the Chinese word for "crisis" is composed of two characters, one meaning "danger" and the other meaning "opportunity. In fact, this is not the case. Nevertheless, the word often hits the mark. While many crises carry danger, they also often present opportunities.
In the case of COVID-19, we can certainly see this happening. To date, more than 5 million people worldwide have died from this viral infection. At the same time, numerous businesses made a lot of money during the pandemic by selling personal protective equipment, tests, therapies, and vaccines.
None of them benefited more financially than Pfizer. In the third quarter alone, the company reported $13 billion in sales of its COVID-19 Comirnaty vaccine. SVB Leerink analyst Jeffrey Porges estimates that Pfizer expects to make a staggering $131 billion on sales of the COVID-19 vaccine by the end of next year. But is this pharmaceutical company stock worth buying?
Let's first look at how Pfizer could make $160 billion on coronavirus over the next two years. First, we need to consider the company's projected revenue of $36 billion in 2021 from Comirnaty.
Porges believes that sales of the vaccine will actually be much higher this year. He expects that approvals and authorizations in many countries for booster doses and for children could boost Comirnaty's total worldwide sales to $59 billion in 2021.
The Wall Street analyst expects vaccine sales to drop to about $48 billion next year. So by the end of 2022, Pfizer's revenue from Comirnaty sales will be $107 billion.
But Comirnaty probably won't be Pfizer's only source of revenue from COVID-19. The company hopes to soon get emergency approval and approval for the oral antiviral drug Paxlovid in the U.S. and other countries.
Purges predicts that sales of Pfizer's COVID-19 pills could be about $95 million this year and $24 billion next year. If you add it all up, Pfizer's total revenue from COVID-19 sales would be about $131 billion over two years.
Pfizer shares the profits from the sale of Comirnaty with its partner BioNTech. Although the company's revenue will be huge, its profits from the vaccine will not be as large.
Sales of the COVID-19 vaccine are also likely to be lower in 2023. Porges, however, predicts that Paxlovid sales will grow to $33 billion in 2023. After 2023, though, the picture becomes less cheerful.
Many investors speculate that COVID-19 will be like the flu, requiring annual vaccinations. But it is too early to judge whether this will actually be the case. If not, Pfizer's revenues will fall markedly over the next few years.
Looking ahead, Pfizer faces a patent cliff beginning in 2026. Several of the company's currently best-selling drugs will lose patent exclusivity in the second half of this decade.
Despite these potential problems, it should be noted that there are three reasons why Pfizer stock is still worth buying.
Let's start with the most compelling one on the list, the dividend. Currently, Pfizer's dividend yields just under 3%. Given the cash flow the company will generate, there is a good chance that the dividend will increase.
Pfizer is also predicted to use its growing cash reserves to make business development deals. The company is expected to license more promising drugs developed by other drugmakers. In addition, many believe that Pfizer will make a major acquisition in the not-too-distant future. The right deals could go a long way toward offsetting the impact of the patent cliff, which is looming in a few years.
Finally, there is the possibility that sales of Comirnaty (or its successors) and Paxlovid will remain strong for a long time to come. COVID-19 could become endemic and bring Pfizer much more money over the next decade than anyone expects.
Given that Pfizer made $13 billion on sales of its coronavirus vaccine in the third quarter alone, it's understandable why investors are wary of the rapidly evolving threat posed by the new variant, dubbed Omicron. If Omicron proves to be as insidious as early reports suggest, it could well become a serious problem for vaccinated people and vaccine manufacturers worldwide.
But the fear of Pfizer's defeat of Omicron is quite premature. In fact, there is probably no company in a better position to solve such a problem as a new option, as an opportunity to rise to the next level.
The dangers of this crisis may not go away. And the opportunities for Pfizer may not disappear either.
U PFEUnitySoftware PFE Some follow-up and cleanup of these two markets. Sometimes I go back and look to see actually did reverse, and how far it moved. On equity markets (which I never trade) I sometimes fail to go back to evaluate and critique. I critique all my trades...and summerize it.
PFE update Possible pennant forming here that could take us to 57$ next week.
over 54.80 is a breakout.
$PFE looking for ATH close...Almost having as good of a day as $MRK, setting up today for an ATH close. Perhaps it will be best to stick with the strong name vs trying to chase a currently unpopular one.
$PFE on watch for blue skies...With all the talk on COVID, might be a reasonable play to just stick with what we know and that people will need to keep getting more vaccines... 1/21/22 $60/$70 call spread at $0.86
Pfe update (Channel trade)Broke out from under that 12yr resistance last Friday. Hit top of the channel yesterday and pulled back to support..
Next stop 57$
PFE Pfizer to All Time HighIf you haven`t bought at my first call, when PFE was $40:
Than you should know that Pfizer’s vaccine with BioNTech SE is on track to be the best-selling drug product on a yearly basis and received backing from a European regulatory panel on Thursday to expand its use into children as young as five.
Still low PE Ratio (TTM) 15.42
Decent Forward Dividend & Yield 1.56 (2.89%)
The stock jumped also on the promise of its antiviral pill!
For me is a Buy even at this level!
PFE weekly Wolfe Wave bearish 11/28A Wolfe Wave is a chart pattern composed of five wave patterns in price that imply an underlying equilibrium price. Investors who use this system time their trades based upon the resistance and support lines indicated by the pattern.
11/28/21 PFEPfizer, Inc. ( NYSE:PFE )
Sector: Health Technology (Pharmaceuticals: Major)
Current Price: $54.00
Breakout price trigger: $54.90
Buy Zone (Top/Bottom Range): $52.00-$48.00
Price Target: $69.70-$71.00
Estimated Duration to Target: 252-268d
Contract of Interest: $PFE 6/17/22 60c
Trade price as of publish date: $2.70/contract
PFIZER - SELL strategyThe daily and weekly chart are starting to suggest a peak in the near future.
The RSI weekly and Daily chart are getting overbought, not extreme, but good enough to becareful.
Strategy sell near $ 57 for a buy-back $ 40.
Stop-loss likely somewhere $ 59
New high PfizerThis new high could be potentially setting a new trend. With the lockdown and the increasing numbers.
Stay safe and well
PFE LongWeekly: Rev. Head & Shoulder, Breakout + revisit neckline
At Support Zone
Daily: trendline break
Entry 42
Stop 40.5
Target 50
Risk management is much more important than a good entry point.
The max Risk of each plan should be less than 1% of an account.
I am not a PRO trader. I trade option to test my trading plan with small cost.
$PFE - Cup breakout watch. Target $62Forming cup with the rim around $52. Break above the rim could send the stock to $62.
Target 1 - $59
Target 2 - $62
Target 3 - $75 (very very long term)
Risk - Unable to break above the rim $52 and retrace back to $45
———————————————————
How to read my charts?
- Matching color trend lines shows the pattern. Sometimes a chart can have multiple patterns. Each pattern will have matching color trend lines.
- The yellow horizontal lines shows support and resistance areas.
- Fib lines also shows support and resistance areas.
- The dotted white lines shows price projection for breakout or breakdown target.
Disclaimer: Do your own DD. Not an investment advice.
Pfeizer. Flat again. PFEThis is beginning to sound like a broken record.
We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe!
Hoping for a handle to form on PfizerI put $PFE Pfizer on my watchlist since the covid-19 pill news & was hoping for a low risk setup to get onboard. Putting a 3 month cup & reversed today after it failed its BO
Hoping this puts in a handle of some sort to get me interested
Accelerating EPS & Sales + Breakout Year
Short PFEProfit taking after another trip up to resistance (Seelink)
Fell out of a rising wedge here today which I think will lead us lower to close that gap at 44.
the exact same thing happen back in august. Ran up on rumor of a Pending FDA covid approval then sells off
ascending channel, gains after earnings, short-time bullishNot financial advice!
We can clearly see the ascending channel of this stock. Even though the stock is running for quite some time now, I don't think it will actually stop before we see $54,XX.
After last earnings the stock gained about 20% and reached the top of channel after 14 trading days. From my point of view, since the last earnings reported were even better and the Covid-medication is on the way, there is no doubt that it will touch the top of channel again within a few days. If it does, it magically gained about 20% within 14 trading days after earnings.
Watch the last high closely, as PFE may get rejected there.
Not financial advice!
Pfizer manipulates the marketPre pandemic this stock was in the process of a bear market. Big handed investors prepared their investors where to move money. With the help of the government they can now force every citizen to take their manufactured "Drug" for life.
...
Big government is working for big business to keep money flowing into their pockets for Life. Gov+Mandates= money for an entirety of human life will go into big pharmaceuticals.
Al those yellow lines are day gaps in money that need to be filled. What will be the last domino and when?
PFE approaching 12 year resistance The last time Pfe touched this resistance was back in August and the rejection was immediately. Here you can see this candlestick is the most bullish one in a decade.
There's some RSI divergence on the monthly
The MFI on daily has lit up and usually means a pullback is coming.
Keep your eye out around 52$-52.50 for some rejection or a breakout. any breakout will require massive vol so I would suspect some company news might leak for a catalyst.. Leits see what happens, I'm here either way
Pfizer | Fundamental Analysis | Must Read ⚡️Pfizer has grown an authority at being first. The pharmaceutical behemoth was the pioneer to introduce a coronavirus vaccine a year ago. Since then, it has had several other successes: bringing the COVID-19 booster to market, getting approval for its vaccine for adolescents, and most recently getting approval for a vaccine for children.
This has been followed by a lot of revenue. Moreover, the company recently raised its revenue forecast for coronavirus vaccines this year to $36 billion. Pfizer also raised its total revenue forecast to at least $81 billion as demand for the company's other drugs grows as well.
At the same time, the company's stock is up about 18% this year. So now the big question is: Is it too late to buy Pfizer stock?
First, let's look at Pfizer's performance now and what may lie ahead. Last week, Pfizer reported a 134 percent increase in third-quarter revenue to $24.1 billion. That includes sales of the coronavirus vaccine.
It's impossible to say exactly how much sales of this drug will grow after the pandemic, but it looks like sales of the vaccine could remain at the "best-seller" level for a long time to come. Experts say the virus will persist into the future, so we need protection - and that means regular vaccinations. As recent studies have shown, immunity declines a few months after the initial vaccination.
Let's take a look at what Pfizer itself says about future vaccine revenues. During its earnings report, the company said that some projections of vaccine revenue for 2022 look "very high," and offered more moderate projections. Pfizer projected vaccine revenue for 2022 at $29 billion, based on the delivery of 1.7 billion doses.
That's still a pretty impressive level. And that figure could be higher. Pfizer can produce 4 billion doses, and the company is still negotiating with governments.
Meanwhile, two elements are helping Pfizer continue to gain market share for coronavirus vaccines: the booster and the use of the vaccine in children and adolescents. The company is just getting started in these areas, so they clearly can help boost orders as countries plan the number of doses needed for next year and beyond.
The competitor's Moderna vaccine is not yet available for teens and children in the U.S. This means that Pfizer has an opportunity to dominate these age groups.
At the same time, Pfizer is moving closer to conquering another COVID-19 market: the treatment market. The company's investigational coronavirus pill is currently in late-stage clinical trials. The company says trial data could be available as early as this quarter. The potential pill could be a game-changer because it could be prescribed immediately after a person is diagnosed with COVID-19 and could be taken at home.
Competing company Merck, however, maybe first on the market with a potential pill treatment. It has already requested approval for its drug. But given the need for such a drug, both companies could generate billions of dollars in revenue in this area.
Analysts talk a lot about coronavirus. But the reality is that Pfizer has many other sources of revenue today - and potential in the future. This means that Pfizer can continue to thrive even if sales of the COVID-19 vaccine stall or decline.
The drivers of today's revenue are seven other drugs. Two of them, the blood-thinning drug Eliquis and the cardiovascular drugs Vyndaqel/Vyndamax, posted double-digit revenue growth in the third quarter. Pfizer has 94 programs in development. Of these, 29 are in phase 3 trials. This is cause for optimism about the company's ability to make up for possible declines in sales of its older drugs.
As mentioned earlier, Pfizer stock is up this year, but the stock is only trading at 10 times earnings guidance. This is a bargain, given Pfizer's near- and long-term growth prospects.
Pfizer's growing return on invested capital and free cash flow are two more reasons to be optimistic about the stock.
Pfizer is also a good bet for income-seeking investors. The company just paid its 331st consecutive quarterly dividend.
So, is it too late to buy Pfizer? Not if you're a long-term investor. Pfizer stock hasn't soared as fast as stocks of biotech companies involved in the fight against the coronavirus. And they're unlikely to do so in the future. But Pfizer has plenty of fuel for incremental earnings growth in the future - and that should lead to sustained, long-term stock price gains.
